Cytosorbents Corp Stock Price, News & Analysis

CytoSorbents Corporation (NASDAQ: CTSO) announced positive results from the CytoSorb Therapy in COVID-19 (CTC) Registry presented at the ESICM Congress. The study involved 100 critically ill COVID-19 patients, showing 90-day survival rates of 74% compared to 52% in the broader ELSO registry. Early initiation of CytoSorb therapy significantly improved outcomes, with reduced inflammatory markers and shorter ECMO durations. The study highlights the efficacy of CytoSorb in addressing severe acute respiratory distress syndrome and supports further research into this treatment paradigm.

CytoSorbents Corporation (NASDAQ: CTSO) has been awarded a Phase I SBIR grant worth $281,835 from the National Institute of General Medical Sciences to advance its blood purification technologies targeting Gram-negative sepsis. This funding will facilitate research on the removal of cytokines and lipopolysaccharide (LPS) endotoxin from septic porcine plasma, critical in combating sepsis, responsible for one in five deaths globally. CEO Phillip Chan emphasized the importance of addressing Gram-negative infections in septic shock, which accounts for a significant portion of hospital-acquired infections.

CytoSorbents Corporation (NASDAQ: CTSO) is set to release its third quarter 2022 operating and financial results on November 3, 2022, after market close. A live conference call and presentation will follow at 4:30 p.m. Eastern. The company is recognized for its innovative blood purification technology aimed at critical conditions in ICU and cardiac surgery. CytoSorb, their leading product, is approved in the EU and used in over 75 countries. With over 179,000 devices utilized as of June 30, 2022, CytoSorb focuses on managing severe inflammatory responses in patients.

CytoSorbents Corporation (NASDAQ: CTSO) presented new data on CytoSorb® at the 36th EACTS Annual Meeting in Milan, highlighting its effectiveness in cardiac surgery. The study involved 130 patients undergoing surgery for Staphylococcal aureus endocarditis. The results showed that CytoSorb significantly reduced postoperative vasopressor requirements (p<0.02) and sepsis-related mortality (8.0% vs. 21.8%, p=0.02). Furthermore, it demonstrated significant improvements in 30-day (17.3% vs. 32.7%, p=0.03) and 90-day mortality (21.3% vs. 40%, p=0.03), emphasizing its potential as a safe therapy in high-risk cardiac surgeries.

CytoSorbents Corporation (NASDAQ: CTSO) announced the upcoming retirement of CFO Kathleen P. Bloch on March 31, 2023, after a decade of service. Bloch will assist as a consultant post-retirement to ensure a smooth transition. Under her leadership, the company raised over $140 million and expanded globally, distributing products in 75 countries. CEO Phillip Chan praised her contributions, which included significant improvements in accounting and investor relations. The company aims for continued growth and FDA approval for its DrugSorb-ATR system.

CytoSorbents Corporation (NASDAQ: CTSO) has been awarded a three-year Phase III contract worth $4.3 million by the U.S. Army Medical Research Acquisition Activity. This contract aims to develop the HemoDefend-BGA™ filter for the creation of freeze-dried universal plasma, which could be rapidly deployed in emergency settings without the need for blood typing. The technology aims to greatly simplify logistics for both military and civilian responders, potentially saving lives during trauma care.

CytoSorbents Corporation (NASDAQ: CTSO) will present at the Dawson James Securities 2022 Small Cap Growth Conference on October 12, 2022, from 2:30-2:55 PM EDT. CEO Dr. Phillip Chan will lead the presentation, and 1x1 meetings with management are available during the event. A live webcast will be accessible via the provided link, and an archived recording will be available on the Company’s website.

CytoSorbents Corporation (NASDAQ: CTSO) announced a $1,977,024 grant from the U.S. Army Medical Research Acquisition Activity to further develop its HemoDefend-BGA™ adsorber. This technology aims to create a universal plasma by removing anti-A and anti-B antibodies, potentially enhancing emergency treatments in critical care. The two-year grant will fund pre-clinical studies to evaluate safety and efficacy. This initiative supports a market estimated at $400 million to $600 million in westernized countries, addressing a significant need for plasma in civilian and military settings.